● It provenly does not cause side effects in mice and humans.

● It is required for normal human fetus growth.

● It is resistant to heat (up to 65 Celsius) and proteases: As a result it has an up to 10 days of half-life time in the human circulation (~4 days in mice).

● It inactivates the inflammatory mediators Lipopolysaccharide and extracellular ATP. The concentration of extracellular ATP around tumors is high; elimination of ATP may contribute to the antitumor effects of PLAP.

● It is an antitumor and anticachectic agent while also protecting the bone marrow and mesenchymal stem cells against the toxic effects of cancer drugs.

● It not only reduces blood glucose in obese diabetic mice along with normalizing high serum level of insulin, but in experimentally induced pancreatitis in mice it also prevents the development of type 3c diabetes.

● It protects human pancreatic insulin producing cells against the toxic effects of saturated fatty acids (palmitic and stearic acids).

● Due to its large effects on visceral fat, in obese mice PLAP practically normalizes high triglyceride levels (something statins cannot do) and substantially (50-60%) reduces the high level of LDL-cholesterol.

● Due to its stimulatory effects on the proliferation of human fibroblasts and keratinocytes, PLAP promotes wound healing both in mice and humans. Due to its positive effects on diabetes, PLAP may prove to be an essential tool to promote healing diabetic wounds (this is open to investigation and then patent protection).

SUMMARY: The company which is willing to invest in large scale production of PLAP will be able to use it for addressing a variety of health issues in a very competitive manner.

AVAILABILITY: IT IS PRESENTLY AVAILABLE FROM COMMERCIAL SOURCES.

RECOMBINANT PLAP HAS ALSO BEEN PRODUCED BY A PLANT, AND THIS TECHNOLOGY CAN BE PURCHASED.